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Abstract
Background: The mammalian Vps10p sorting receptor family is a group of 5 type I membrane
homologs (Sortilin, SorLA, and SorCS1-3). These receptors bind various cargo proteins via their
luminal Vps10p domains and have been shown to mediate a variety of intracellular sorting and
trafficking functions. These proteins are highly expressed in the brain. SorLA has been shown to be
down regulated in Alzheimer's disease brains, interact with ApoE, and modulate Aβ production.
Sortilin has been shown to be part of proNGF mediated death signaling that results from a complex
of Sortilin, p75NTR and proNGF. We have investigated and provide evidence for γ-secretase
cleavage of this family of proteins.
Results: We provide evidence that these receptors are substrates for presenilin dependent γ-
secretase cleavage. γ-Secretase cleavage of these sorting receptors is inhibited by γ-secretase
inhibitors and does not occur in PS1/PS2 knockout cells. Like most γ-secretase substrates, we find
that ectodomain shedding precedes γ-secretase cleavage. The ectodomain cleavage is inhibited by
a metalloprotease inhibitor and activated by PMA suggesting that it is mediated by an α-secretase
like cleavage.
Conclusion: These data indicate that the α- and γ-secretase cleavages of the mammalian Vps10p
sorting receptors occur in a fashion analogous to other known γ-secretase substrates, and could
possibly regulate the biological functions of these proteins.
Background
γ-Secretase is a multi-component protease complex com-
prised of Presenilin (PS) 1 or 2 with Aph-1, Pen-2, and
Nicastrin [1,2] that cleaves type I membrane proteins
within their transmembrane domains. γ-Secretase cata-
lyzes a number of important physiological and patho-
physiological cleavages. Following ectodomain cleavage
of the amyloid precursor protein (APP) [3] by β-secretase,
γ-secretase cleavage releases the amyloid beta peptide (Aβ)
that accumulates in the brains of patients with Alzhe-
imer's disease (AD) [4]. γ-Secretase also plays a key role in
mediating signaling via the Notch receptors [5-7]. In most
cases, knockout of presenilin or other components of the
γ-secretase complex produces an embryonic lethal pheno-
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type, that resembles the phenotype produced by knockout
of Notch 1.
To date, more than 25 γ-secretase substrates have been
identified. [8-28]. All identified γ-secretase substrates are
type I transmembrane proteins [29] and contain a puta-
tive stop transfer sequence immediately following the
transmembrane region [30]. In most cases, ectodomain
shedding precedes intramembrane γ-secretase cleavage
[31]. For a growing lists of substrates, γ-secretase cleavage
has been shown to mediate downstream signaling events
[32].
Although many proteases preferentially cleave at consen-
sus sequences within the substrate, no consensus
sequence for cleavage by γ-secretase has been identified. γ-
Secretase cleavage always occurs within a putative hydro-
phobic transmembrane region, but a variety of different
sites are cleaved even in a single substrate. Alignment of γ-
secretase substrate transmembrane domains provides lit-
tle insight into the sequence requirements for proteolysis
to occur (Figure 1a) [33]. Likewise mutations of cleavage
sites have provided little definitive information on the
nature of the cleavage, though several models have been
proposed [34].
Following ectodomain shedding, γ-secretase cleavage lib-
erates both the cytoplasmic fragment and a small secreted
peptide. For several substrates the liberated cytoplasmic
domain has been shown to translocate to the nucleus
where it is involved in nuclear signaling (Notch ErbB4,
Delta-1 Jagged, APLP1/2). This process is more generally
referred to as regulated intramembrane proteolysis (RIP).
RIP of Notch has been intensively studied. Ligand binding
to the Notch extracellular domain results in ectodomain
cleavage, which is then followed by γ-secretase cleavage.
Once liberated the notch intracellular domain (NICD)
translocates to the nucleus where it binds to CSL family of
transcription factors [35,36]. Notch binding to CSL has
been shown to convert CSL from a transcriptional repres-
sor to a transcriptional activator [5]. Analogously nuclear
signaling of the CD44 [37,38] and N-cadherin [39] cyto-
plasmic domains following γ-secretase cleavage is indi-
rectly achieved through CBP (CREB-binding protein)
activation or suppression, respectively. In some cases
nuclear translocation of the cytoplasmic domain is not
required for signaling following γ-secretase cleavage
[8,13,14,40]. Not all γ-secretase substrates appear to
undergo RIP, as ligand binding is not necessary for the ini-
tiation of cleavage. For example, APP does not appear to
require ligand association in order to initiate ectodomain
shedding which occurs prior to γ-secretase cleavage.
In most cases, signaling initiated by γ-secretase cleavage
appears to be an activation event. However, cleavage of
the substrate deleted in colorectal cancer (DCC) attenu-
ates receptor-mediated intracellular signaling pathways
that are critical in regulating glutamatergic synaptic trans-
mission and memory processes [18,41].
Because of their topologic similarity to other γ-secretase
substrates and evidence for ectodomain shedding [42]
(Figure 1a), we hypothesized that the mammalian Vps10p
containing family of proteins might be γ-secretase sub-
strates. Sortilin, SorLA and SorCS1, 2, and 3 comprise the
five identified mammalian Vps10p sorting receptors and
have a number of features in common. First, all are type I
membrane proteins (Figure 1b). Second, all contain a
luminal/extracellular cysteine-rich Vps10p domain
homologous to the binding domain of the yeast sorting
receptor for carboxypeptidase Y. Third, all contain a puta-
tive furin cleavage site. SorCS1-3 and SorLA also contain
additional extracellular domains thought to be involved
in ligand binding (Figure 1b). Sortilin is also known as
neurotensin receptor 3 or gp95, and SorLA is often called
LR11. These receptors are hypothesized to have pleio-
tropic functions in chaperoning and targeting various car-
goes bound to their luminal Vps10p domains between
various intracellular organelles [43,44].
These sorting receptors are expressed at high levels in the
CNS and in neurons [44-46]. Sortilin is part of the
machinery that governs cell survival in developing neuro-
nal tissue and a key determinant in the induction of post-
traumatic neuronal apoptosis [47]. It also mediates rapid
endocytosis of lipoprotein lipase [48], neurotensin [49],
and the proform of nerve growth factor [47]. Sortilin has
been shown to target proteins in the Golgi for transport to
late endosomes. Of its many sorting and signaling func-
tions, Sortilin was shown to play a role in p75NTR "death
signaling". The cell death signal is a result of a complex of
p75NTR, Sortilin and the precursor form of nerve growth
factor (proNGF) [47] or pro brain-derived neurotrophic
factor [50].
Recent data have suggested a role for SorLA in AD. SorLA
was shown to be a receptor for, and interact with, ApoE
[51-54]. In addition, it is reduced in AD brains versus age
matched controls, interacts with APP [55] and regulates
Aβ production [56,57].
we provide evidence that Sortilin, SorCS1b and SorLA are
sequentially cleaved by an α-secretase like activity fol-
lowed by γ-secretase. α-Secretase cleavage results in secre-
tion of a large extracellular domain of the Vps10p
substrates and γ-secretase liberates a COOH-terminal frag-
ment (CTF) from the membrane. These data extend very
recent studies demonstrating that Sortilin, SorCS1,
SorCS2, SorCS3, and SorLA undergo ectodomain shed-Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
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ding [42] and that SorLA can undergo γ-secretase cleavage
[28].
Results
Evidence for sequential α- and γ-secretase cleavage of 
Sortilin
HEK 293T cells were transiently transfected with Sortilin
containing a V5 epitope tag at the COOH-terminus
(SorV5) and treated with a variety of inhibitors or PMA.
The epitope tagged SorV5 construct was used because we
have been unable to obtain a reliable anti-sortilin COOH-
terminal antibody. Cell lysates and media from the tran-
siently transfected cells were analyzed by SDS PAGE and
Western blotting. Consistent with previous studies show-
ing that the untagged Sortilin holoprotein is a ~95 kDa
glycoprotein [58], transfection of the SorV5 resulted in
Schematics of γ-secretase substrates and the mammalian Vps10p proteins Figure 1
Schematics of γ-secretase substrates and the mammalian Vps10p proteins. a) Alignment of the transmembrane 
domains and juxtamembrane region of known γ-secretase substrates The number of additional amino acids in the cytoplasmic 
domain following the sequence shown is indicated by "+ aa". b) A schematic of the human Vps10p containing proteins is 
shown. Sortilin is a 95 kDa glycoprotein. SorCS1, 2, and 3 contain a leucine rich domain and are ~130 kDa. The largest of the 
homologs, SorLA is 250 kDa and contains a host of receptor binding domains including 14 different low density lipoprotein 
receptor sites, and EGF repeat, and a fribronectin type III repeat.
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expression of a 95 kDa protein that was detected both by
an anti-Sortilin NH2-terminal antibody (not shown) and
anti-V5 (Figure 2a). In addition, a SorV5 CTF was detected
with the anti-V5 antibody at ~16 kDa (Figure 2a). This
band was not detected by the NH2-terminal Sortilin anti-
body (not shown). γ-Secretase inhibitor treatment mark-
edly increased the ~16 kDa SorV5 CTF in cell lysates of
cells transiently overexpressing SorV5 (Figure 2a), but did
not appreciably alter the amount of soluble Sortilin (sSor)
that was detected in the media with an anti-Sortilin NH2-
terminal antibody but not anti-V5 (Figure 2a). Activation
of protein kinase C by PMA has been shown to enhance
ectodomain shedding of APP by α-secretase [59-62] and
resulted in an increase in sSor detected in the media (Fig-
ure 2a). GM6001, a broad spectrum hydroxamic acid
based inhibitor of matrixmetalloproteases and disin-
tegrin-metalloproteases [63], has been shown to inhibit
α-secretase cleavage of APP and decreased sSor levels
detected in the media. Both GM6001 and PMA treatment
decreased total levels of the 16 kDa SorV5 CTF (Figure 2a).
Anti-β-actin was used to demonstrate loading consistency
between wells.
The increase in 16 kDa sorV5 CTF resulting from γ-secre-
tase inhibition suggested that the SorV5 CTF was a precur-
sor to γ-secretase cleavage. We then expressed SorV5 in
cells lacking PS1 and PS2. Transfection of SorV5 into PS-/-
MEF cells resulted in an accumulation of the 16 kDa CTF
(Figure 2b). Cotransfection of PS-/- MEF with SorV5 and
either PS1 wt or a familial Alzheimer's disease linked
mutant PS1 (M139V) caused the 16 kDa SorV5 CTF band
to almost completely disappear (Figure 2b). Cotransfec-
tion of a dominant negative PS1 aspartate mutant
(D385E) did not reduce levels of the 16 kDa SorV5 CTF.
As expected, PS1 wt and M139V PS1 expression resulted
in generation of endoproteolyzed PS1 CTF (Figure 2b);
and expression of PS1 D385E resulted in accumulation of
the PS1 holo protein (Figure 2b).
Sortilin is processed into a CTF that is increased by γ-secretase inhibition or knockout Figure 2
Sortilin is processed into a CTF that is increased by γ-secretase inhibition or knockout. a) HEK 293T cells tran-
siently transfected with sorV5 produce a ~95 kDa holoprotein labeled by anti-V5 and anti-Sor NT antibody (not shown). A 
~16 kDa CTF of SorV5 is detected by an anti-V5 antibody is present in the cell lysate, and anti-SorNT detects a secreted frag-
ment of ~95 kDa (sSor) that does not label with anti-V5. The anti-V5 positive SorV5 CTF increased with γ-secretase inhibitor 
treatment (LY411,575 and compound E) and decreased with either PMA or a metalloprotease inhibitor, GM6001. sSor 
increased upon PMA treatment and decreased upon treatment with a metalloprotease inhibitor, GM6001. b) Mouse embry-
onic fibroblasts that are PS-/- were transiently transfected with SorV5 plus empty vector, PS1, PS1 M139V, or PS1 D385E. In the 
absence of PS1 or the presence of a dominant negative PS1 mutant (D385E) the levels 16 kDa SorV5 CTF are markedly 
increased. However, cotransfection of PS1 wt or PS1 familial Alzheimer's disease linked mutant (M139V) and SorV5 lead to an 
almost complete reduction in the levels of 16 kDa anti-V5 positive SorV5 CTF. Anti-β-actin was included as a loading control 
and anti-PS1ct antibody demonstrated that PS1 wt and M139V underwent endoproteolysis whereas D385E did not.
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γ-secretase processing of SorV5 CTF in lipid rafts
In figure 2b the 16 kDa CTF, a putative γ-secretase sub-
strate, increased when no PS was present. Under condi-
tions amenable to γ-secretase cleavage, the 16 kDa band
diminished but a smaller product band was not detected.
It has been demonstrated that γ-secretase activity is
enriched by sucrose gradient fractionation into choles-
terol rich microdomains called lipid rafts [64-67]. To fur-
ther confirm that the 16 kDa SorV5 CTF is a γ-secretase
substrate, cells stably overexpressing SorV5 were lysed in
2% CHAPSO to maintain the γ-secretase complex and
sucrose gradient fractionated as described in the Methods.
Fractions were analyzed by SDS PAGE and Western blot-
ting (Figure 3a). As previously shown, PS1 CTF and NH2-
terminal fragment (NTF) were enriched in the buoyant
fractions 4 and 5 whereas holo PS1 was primarily found
in more dense fractions 10, 11 and 12 (figure 3a). GS27,
a known lipid raft marker, was enriched in the buoyant
fractions as shown previously [64]. However, EEA1, an
early endosomal marker, was found primarily in dense
fractions. The 95 kDa holo SorV5 fractionated to both the
buoyant and dense fractions much like holo APP [64]. A
SorV5 CTF (~16 kDa) was enriched in the buoyant fac-
tions (Figure 3a, "4°C"). Incubation of the all fractions at
37°C for two hours generated a smaller SorV5 CTF (~13
kDa) that was only detected in buoyant fractions (Figure
3 "37°C"). These data provide evidence that the lipid raft
portion of the sucrose gradient contained all the compo-
nents necessary to generate a smaller SorV5 CTF upon
incubation at 37°C.
Having observed the in vitro generation of a smaller SorV5
CTF in fractions 4 and 5 as a result of incubating at 37°C
for 2 hours, we repeated the experiment with cells that
had been pretreated with 50 µM IL-aldehyde, a γ-secretase
inhibitor. These cells were lysed and sucrose gradient frac-
tionated. Buoyant fractions 4 and 5 were combined and
equal aliquots were incubated at 37°C for two hours plus
and minus γ-secretase inhibitors. During the same period
a negative control was incubated at 4°C for two hours. As
shown in Figure 3a, when the buoyant fractions were
incubated at 37°C for two hours a smaller SorV5 CTF
band was generated (figure 3b DMSO). In the sample that
remained at 4°C during the incubation period or those
incubated in the presence of γ-secretase inhibitors no
smaller SorV5 CTF was detected (Figure 3b). Furthermore,
generation of the smaller SorV5 CTF was inhibited by
another  γ-secretase inhibitor (LY411,575) in a dose
dependant fashion (Figure 3c). Anti-PS1NT antibody was
used to demonstrate loading consistency.
SorCS1b, evidence for α and γ-secretase processing of a 
second mammalian Vps10p
To further establish that the mammalian Vps10p contain-
ing family members are processed by α and γ-secretase
similar experiments were performed with SorCS1b tagged
with V5 at the COOH-terminus (SorCS1bV5). Consistent
with previous studies showing that the untagged SorCS1b
or His tagged holoprotein was a ~130 kDa [68], transfec-
tion of the SorCS1bV5 resulted in expression of a 130 kDa
protein that was detected by anti-V5 (figure 4a). Transfec-
tion of SorCS1bV5 into PS-/- MEF cells resulted in an
increase in the 13 kDa CTF (Figure 4a). Cotransfection of
PS-/- MEF with SorCS1bV5 and either PS1 wt or a familial
Alzheimer's disease linked mutant PS1 (M139V) caused a
decrease in the 13 kDa SorV5 CTF band (Figure 4a).
Cotransfection of a dominant negative PS1 aspartate
mutant (D385E) did not reduce levels of the 13 kDa
SorCS1bV5 CTF. Sucrose gradient fractionation of a cell
lysate from HEK cells stably overexpressing SorCS1bV5
lead to an enrichment of a ~13 kDa SorCS1bV5 CTF in
buoyant fractions at 4 and 5 (Figure 4b). Incubating the
fractions at 37°C for two hours generated a faintly detect-
able anti-V5 positive band at ~10 kDa. More consistent
than the detection of this band, was a decrease in the 13
kDa SorCS1bV5 CTF band observed after incubation at
37°C for two hours (Figure 4c and 4d). The decrease in
the ~13 kDa SorCS1bV5 band was inhibited by both
Compound E (Figure 4c) and LY411,575 in a concentra-
tion dependent fashion (Figure 4d). Detection of the sol-
uble SorSC1b NH2-terminus in the media was not
possible due to the lack of a reliable NH2-terminal anti-
SorCS1 antibody.
PS dependant SorLA processing
Using a wt SorLA construct and a COOH-terminal anti-
SorLA antibody (anti-SorLAct) we have obtained evidence
that that SorLA is a γ-secretase substrate as well. The SorLA
holoprotein was detected by the SorLA COOH-terminal
antibody at 250 kDa (Figure 5) consistent with previous
reports [69]. Transfection of SorLA into PS-/- MEF cells
resulted in accumulation of a 15 kDa SorLA CTF detected
by an anti-SorLAct antibody (Figure 5). However, cotrans-
fections with SorLA and either PS1 wt or an familial
Alzheimer's disease linked mutant PS1 (M139V) caused a
decrease in the 15 kDa SorLA CTF (Figure 5). Cotransfec-
tion of sorLA with a dominant negative PS1 aspartate
mutant (D385E) did not alter levels of the 15 kDa SorLA
CTF.
Discussion
To date, more than 25 γ-secretase substrates have been
identified (Figure 1a). γ-Secretase cleavage of certain sub-
strates mediates normal physiologic signaling. Given the
growing list of substrates, it has been postulated that γ-
secretase may function much like the proteosome of the
membrane assisting in the degradation of type I trans-
membrane proteins by liberating them from the mem-
brane [70]. This notion may be supported by the
promiscuity with which γ-secretase cleaves multiple sub-Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
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strates at a variety of different sites (Figure 1a). It is possi-
ble that overexpression of type I transmembrane proteins
may result in non-physiologic γ-secretase cleavage. How-
ever, to date, all γ-secretase substrates initially identified
using overexpression studies in eukaryotic cells have
proven to be authentic endogenous substrates. Indeed,
numerous  γ-secretase substrates like APP, Notch, and
CD44 have withstood the scrutiny of genetic, biochemi-
Sucrose gradient fractionation of SorV5 overexpressing cells demonstrates enrichment of the 16 kDa CTF in buoyant "lipid  raft" fractions and generation of a smaller SorV5 CTF Figure 3
Sucrose gradient fractionation of SorV5 overexpressing cells demonstrates enrichment of the 16 kDa CTF in 
buoyant "lipid raft" fractions and generation of a smaller SorV5 CTF. a) HEK cells stably overexpressing sorV5 were 
sucrose gradient fractionated and 1 ml fractions were collected from the top. Each fraction was analyzed by SDS PAGE on 12% 
XT Bis-Tris SDS PAGE (MES Buffer) and Western blotting. "4°C" were samples that were maintained at 4°C until SDS PAGE 
loading buffer was added. "37°C" indicates samples that were incubated at 37°C for 2 hours and then prepared as western 
samples. A smaller SorV5 CTF was detected in fractions 4 and 5 of the 37°C incubated sample. Anti-V5 antibody detected the 
SorV5 holo protein at 95 kDa, a CTF at 16 kDa and a smaller CTF in the "37°C" lanes 4 and 5. Anti-GS27 was used as a lipid 
raft marker (fractions 4–5), Anti-EEA1 is an early endosomal marker that was not found in lipid raft. PS1 CTF and NTF were 
enriched in raft fractions 4 and 5. b) HEK cells stably overexpressing sorV5 were pretreated with a γ-secretase inhibitor (IL-
aldehyde) for 30 hours and sucrose gradient fractions 4, 5 were combined and analyzed for generation of the smaller SorV5 
CTF. Samples were equally divided and incubated at 37°C (4°C for control) in the absence or presence of γ-secretase inhibi-
tors, LY411575, and Compound E. A smaller SorV5 CTF band was detected as a result of incubation at 37°C but was blocked 
by γ-secretase inhibitors. c) Samples were prepared as in b). Generation of the smaller SorV5 CTF was inhibited in a dose 
dependant fashion by a γ-secretase inhibitor, LY411,575. Anti-PS1NT demonstrates the loading consistency.
c
a
bMolecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
Page 7 of 11
(page number not for citation purposes)
PS dependent γ-secretase cleavage of SorCS1bV5 in lipid rafts Figure 4
PS dependent γ-secretase cleavage of SorCS1bV5 in lipid rafts. a) Mouse embryonic fibroblasts that are PS-/- were 
transiently transfected with SorCS1bV5 in the same fashion as figure 3a. Cells transiently transfected with sorCS1bV5 produce 
a ~130 kDa holoprotein labeled by anti-V5. In the absence of PS1 or the presence of a dominant negative PS1 mutant (D385E) 
the levels 13 kDa SorCS1bV5 CTF are markedly increased. However, cotransfection of PS1 wt or PS1 familial Alzheimer's dis-
ease linked mutant (M139V) and SorCS1bV5 lead to a reduction in the levels of 13 kDa anti-V5 positive SorCS1bV5 CTF. Anti-
β-actin was included as a loading control and anti-PS1ct antibody demonstrated that PS1 wt and M139V underwent endoprote-
olysis whereas D385E did not. b) HEK cells stably overexpressing sorCS1bV5 were sucrose gradient fractionated and 1 ml 
fractions were collected from the top. Each fraction was analyzed by SDS PAGE on 12% XT Bis-Tris SDS PAGE (MES Buffer) 
and Western blotting. "4°C" were samples that were maintained at 4°C until SDS PAGE loading buffer was added. "37°C" indi-
cates samples that were incubated at 37°C for 2 hours and then prepared as western samples. A faint SorCS1bV5 CTF was 
detected in fractions 4 and 5 of the 37°C incubated sample. Anti-V5 antibody detected the SorV5 holo protein at 130 kDa, a 
CTF at 13 kDa and a smaller CTF in the "37°C" lanes 4 and 5. Anti-GS27 was used as a lipid raft marker (fractions 4–5), Anti-
EEA1 is an early endosomal marker that was not found in lipid raft. PS1 CTF and NTF were enriched in raft fractions 4 and 5. 
c) HEK cells stably overexpressing sorCS1bV5 were pretreated with a γ-secretase inhibitor (IL-aldehyde) for 30 hours and 
sucrose gradient fractions 4, 5 were combined and analyzed for generation of the smaller SorCS1bV5 CTF. Samples were 
equally divided and incubated at 37°C (4°C for control) in the absence or presence of γ-secretase inhibitors, LY411575, and 
Compound E. A smaller SorV5 CTF band was not detected as a result of incubation at 37°C but the disappearance of the 13 
kDa SorCS1bV5 CTF was blocked by γ-secretase inhibitors. d) Samples were prepared as in b). Disappearance of the 
SorCS1bV5 CTF was inhibited in a dose dependant fashion by a γ-secretase inhibitor, LY411,575. Anti-PS1NT demonstrates 
the loading consistency.
a
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cal, animal model data that establish both their authentic-
ity as true γ-secretase substrates and the physiologic
relevance of γ-secretase cleavage.
Sortilin, SorCS1b and SorLA are all members of the mam-
malian Vps10p sorting receptor family. In this manuscript
we provide several lines of evidence that these proteins are
γ-secretase substrates. We detect truncated CTF derived
from COOH-terminally V5 epitope tagged Sortilin and
SorCS1b and untagged SorLA. These CTF appear to be
derived from the holoproteins by an α-secretase like activ-
ity. γ-Secretase inhibitors and expression of the proteins in
presenilin knockout cells results in marked accumulation
of these CTF, a phenomena reversed by expression wt or
FAD-linked mutant PS1. These CTF are enriched in buoy-
ant lipid raft fractions where γ-secretase activity resides.
Incubation of SorV5 or SorCS1bV5 CTF containing raft
fractions leads to generation of a smaller cleavage product
in the case of Sortilin and a decrease of the CTF in the case
of SorCS1bV5. The generation of the smaller SorV5 CTF
and the decrease in SorCS1bV5 CTF are inhibited by a γ-
secretase inhibitor. Collectively these data indicate that γ-
secretase has the capacity to cleave overexpressed Sortilin,
SorCS1b and SorLA.
During the preparation of this manuscript evidence was
reported that SorLA was a γ-secretase substrate [28]. Bohm
et al demonstrated that Myc tagged SorLA underwent PS
dependent  γ-secretase processing and that following γ-
secretase cleavage the cytoplasmic portion was found in
the nucleus [28]. Combined with our data, demonstrating
that Sortilin, SorCS1b, and SorLa are γ-secretase sub-
strates, these data provide evidence that the entire family
of mammalian Vps10p containing type I proteins may
contain important biologically active signaling peptides
in their COOH-termini.
Studies showing intramembrane γ-secretase cleavage of
endogenous Vps10p sorting receptor will be needed to
show that these proteins are in fact authentic γ-secretase
substrates. As noted before it is unlikely that the overex-
pression studies performed here will be misleading. Given
the complex trafficking, sorting, and signaling functions
mediated by mammalian Vps10p sorting receptors it will
be interesting to determine whether γ-secretase cleavage
regulates the normal function of these proteins. Indeed, it
may be that some of the trafficking deficits in PS deficient
cells could be attributed to the lack of γ-secretase cleavage
of several Vps10p proteins. Though speculative there is
some evidence that Vps10p receptors may play a role in
AD and in neuronal death. SorLA has been shown to be
down regulated in AD, and plays a role in APP trafficking
and Aβ production [56,71]. Neuronal death signaling was
shown to result from a complex of two γ-substrates, Sorti-
lin and p75NTR [13,14], in conjunction with proNGF or
proBDNF [47]. Additional studies are needed to clarify the
physiologic and possible pathologic role of γ-secretase
cleavage of mammalian Vps10p sorting receptors.
Materials and methods
DNA constructs
Full length Sortilin and SorCS1b plasmid constructs were
purchased from Origene. A V5 epitope was cloned into
the pCMV6-XL plasmid at the COOH-terminus immedi-
ately preceding the stop codon (SorV5 and SorCS1V5).
SorLA wt plasmid was described previously [57]. PS1 wt,
M139V, and D385E were described previously [34]. All
constructs were verified by sequencing.
DNA transfection of PS-/- MEF cells
Mouse embryonic fibroblasts (MEF) deficient in both PS1
and PS2 (PS-/-) were characterized previously [72]. Effi-
cient transfection of these cells was achieved using the
Amaxa nucleofector system. Briefly, using the Amaxa MEF
PS dependent cleavage of SorLA CTF Figure 5
PS dependent cleavage of SorLA CTF. Mouse embry-
onic fibroblasts that are PS-/- were transiently transfected 
with SorLA in the same fashion as figure 3a. Cells transiently 
transfected with SorLA produce a ~250 kDa holoprotein 
labeled by anti-V5. In the absence of PS1 or the presence of a 
dominant negative PS1 mutant (D385E) the levels 15 kDa 
anti-SorLAct positive SorLA CTF markedly increased. 
Cotransfection of PS1 wt or PS1 familial Alzheimer's disease 
linked mutant (M139V) and SorLA wt lead to a reduction in 
the levels of 15 kDa anti-SorLA positive SorLA CTF. Anti-β-
actin was included as a loading control and anti-PS1ct anti-
body demonstrated that PS1 wt and M139V underwent 
endoproteolysis whereas D385E did not.Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
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kit 2, 3 µg of DNA and 3 × 10^6 cells/reaction the trans-
fection was performed with the "O-05" mouse neuron
program. Transfected cells were plated on 10 cm plate
with 8 ml of growth media. Cells were harvested after 24
hours.
SorV5 and SorCS1bV5 stable cell lines and culture
Human embryonic kidney (HEK) 293 cells were trans-
fected in reduced serum Opti-Mem (Gibco) with 2 µg of
DNA and 8 µl of Fugene. Cells were incubated for 6 hours
and then allowed to equilibrate in standard growth media
(DMEM 2% fetal bovine serum, 8% normal calf serum,
1% penicillin streptomycin) for 24 hours. Selection anti-
biotic was then added to the cells and maintained
throughout the experiments. Transient expression experi-
ments were performed the same but with HEK 293T cells.
Cells treated with inhibitors were incubated for 18 hours
using the concentration reported and 1% DMSO. phorbol
12-myristate-13-acetate (PMA) treatment was performed
for 4 hours.
γ-secretase inhibitors
Inhibitors were all generated by the Mayo Clinic Chemis-
try core using published methods for each. All com-
pounds were verified by NMR and Mass Spectroscopy.
Lysis, antibodies, and Western blotting
Cells were lysed in 1% triton × 100 with 1× complete pro-
tease inhibitor (Roche) unless otherwise stated. Cell
lysates were then spun at 14,000 RPM for 2 minutes to
remove nuclei. BioRad XT loading buffer with reducing
solution was added to each sample. SDS-PAGE was per-
formed using BioRad Criterion gel system. 12% Bis-Tris
XT gels were used unless otherwise stated with BioRad
MES buffer. Gels were transferred to Millipore low-fluor
PVDF for 90 minutes and 160 volts. Membranes were
blocked in caesine (0.25%) and phosphate buffered
saline solution and primary antibodies were used at the
reported concentration in the blocking solution overnight
at 4°C. Anti-V5 (Invitrogen) and anti-β-actin antibody
(Sigma) antibodies were used at 1:1000. The anti-PS1 NTF
(A4 from Dr. Paul Fraser) antibody I think) and anti-PS1
CTF (490) were used at 1:1000. The anti-SorLAct antibody
was used at 1:500 [57]. Fluorescent antibodies containing
either the 680 or 800 fluorophore were incubated with the
membrane for 1 hour at room temperature at 1:20,000.
Fluorescently labeled protein detection was performed
using the Odyssey Scanner.
Gradient fractionation
Sucrose gradients were run as described previously [64].
Briefly, cells were washed with 5 mL of ice cold PBS (pH
7.4) and lysed in 2.5 mL of 2% CHAPSO 0.15 M Na Cit-
rate (pH 7.0) with 1× protease inhibitor cocktail (com-
plete PI, Roche). The cleared lysate was then sequentially
diluted with sucrose containing 0.15 M Na Citrate (pH
7.0) so that the final concentration of CHAPSO was
0.25% and sucrose was 45%. Four ml of this homogenate
was then applied to the bottom of the centrifuge tube, and
sequentially overlaid with 4 ml of 0.15 M Na Citrate (pH
7.0), 35% sucrose, 0.25% CHAPSO followed by 4 ml of
0.15 M Na Citrate (pH 7.0), 5% sucrose, 0.25% CHAPSO.
The gradient was centrifuged for 19 hrs at 39,000 rpm in
an SW-41 Ti rotor (Beckman) at 4°C. Following centrifu-
gation, 1 mL fractions were collected from the top of the
gradient.
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